Trial Profile
A phase II multicentre randomised, parallel group, double-blind, placebo-controlled study of ZD1839 (Iressa) (250mg tablet) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naive patients with advanced (stage IIIB or IV) non-small cell lung cancer and poor performance status
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms INSTEP
- Sponsors AstraZeneca
- 01 Jun 2016 Status changed from active, no longer recruiting to completed.
- 10 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 18 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.